Pura Vida Investments LLC Has $5.21 Million Stock Holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Pura Vida Investments LLC cut its holdings in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 41.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 113,041 shares of the company's stock after selling 78,898 shares during the quarter. Establishment Labs comprises 16.5% of Pura Vida Investments LLC's investment portfolio, making the stock its largest holding. Pura Vida Investments LLC owned approximately 0.40% of Establishment Labs worth $5,208,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Barclays PLC increased its stake in Establishment Labs by 9,643.3% during the third quarter. Barclays PLC now owns 31,471 shares of the company's stock valued at $1,362,000 after acquiring an additional 31,148 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Establishment Labs by 89.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 41,351 shares of the company's stock worth $1,789,000 after purchasing an additional 19,531 shares in the last quarter. Assenagon Asset Management S.A. bought a new stake in shares of Establishment Labs during the fourth quarter valued at approximately $12,898,000. Point72 Asset Management L.P. raised its stake in shares of Establishment Labs by 210.8% in the third quarter. Point72 Asset Management L.P. now owns 49,400 shares of the company's stock valued at $2,138,000 after purchasing an additional 33,507 shares in the last quarter. Finally, Bamco Inc. NY lifted its position in Establishment Labs by 13.6% in the third quarter. Bamco Inc. NY now owns 489,386 shares of the company's stock worth $21,176,000 after purchasing an additional 58,611 shares during the period. 72.91% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

Separately, Stephens restated an "overweight" rating and issued a $52.00 price objective on shares of Establishment Labs in a research note on Thursday, March 6th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Establishment Labs has a consensus rating of "Moderate Buy" and an average target price of $57.40.

Establishment Labs Price Performance

Shares of NASDAQ:ESTA traded down $4.75 during midday trading on Thursday, reaching $36.84. The company's stock had a trading volume of 444,557 shares, compared to its average volume of 423,630. Establishment Labs Holdings Inc. has a fifty-two week low of $28.16 and a fifty-two week high of $60.12. The business's fifty day simple moving average is $36.68 and its 200-day simple moving average is $40.78. The company has a debt-to-equity ratio of 5.94, a current ratio of 3.62 and a quick ratio of 2.29. The company has a market capitalization of $1.06 billion, a P/E ratio of -14.28 and a beta of 0.95.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.34). The company had revenue of $44.51 million for the quarter, compared to analyst estimates of $44.45 million. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. As a group, equities research analysts expect that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.